Idexx Laboratories Accrued Liabilities, Current decreased by 14.4% to $453.55M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.6%, from $490.69M to $453.55M. Over 5 years (FY 2020 to FY 2025), Accrued Liabilities, Current shows an upward trend with a 5.0% CAGR.
A steady increase relative to revenue may indicate rising operational costs or changes in payment timing.
These are short-term obligations for expenses that have been incurred but not yet invoiced or paid by the end of the rep...
Standard across all industries for tracking short-term operational obligations.
current_liabilities_accrued_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $392.68M | $431.05M | $458.91M | $409.56M | $387.51M | $405.99M | $433.66M | $403.60M | $399.43M | $420.31M | $478.71M | $476.25M | $541.12M | $511.05M | $502.12M | $490.69M | $416.98M | $488.86M | $530.15M | $453.55M |
| QoQ Change | — | +9.8% | +6.5% | -10.8% | -5.4% | +4.8% | +6.8% | -6.9% | -1.0% | +5.2% | +13.9% | -0.5% | +13.6% | -5.6% | -1.7% | -2.3% | -15.0% | +17.2% | +8.4% | -14.4% |
| YoY Change | — | — | — | — | -1.3% | -5.8% | -5.5% | -1.5% | +3.1% | +3.5% | +10.4% | +18.0% | +35.5% | +21.6% | +4.9% | +3.0% | -22.9% | -4.3% | +5.6% | -7.6% |